Glaukos Corporation (GKOS)

Glaukos (GKOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Glaukos (GKOS) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimate...

Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.

Glaukos Corporation (NYSE:GKOS ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations and Corporate Affairs Tom Burns - Ch...

Glaukos (GKOS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.70 per share a year ago.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.